Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid


Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8-10 during the most important week in healthcare investment forums at the Hilton San Francisco Union Square.


Notice to attend the Annual General Meeting of Shareholders of Immune Pharmaceuticals

The shareholders of Immune Pharamceuticals, Inc. (First North: IMNP), (the "Company") are hereby convened to the 2017 Annual General Meeting (the "AGM") to be held on Thursday, 25 January 2018 at 4:00 PM Central European Time (CET) at the offices of Nixon Peabody LLP, 55 West 46th Street, New York, New York 10036. 


Immune Pharmaceuticals Announces Change in Certifying Accountant

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Audit Committee of the Company notified BDO USA, LLP ("BDO") the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017, that the Company and its Audit Committee had determined to dismiss BDO effective as of December 7, 2017. On and effective as of December 7, 2017, the Company entered into an engagement letter with Marcum, LLP ("Marcum") as approved by the Audit Committee, and engaged Marcum to act as the Company's independent registered public accounting firm.


Immune Pharmaceuticals Announces 2017 Annual Shareholder Meeting

Englewood Cliffs, NJ, USA - December 13, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Company filed a preliminary proxy statement with the United States Securities and Exchange Commission ("SEC") on December 8, 2017 in connection with the Company's 2017 Annual Meeting of Stockholders, which is proposed to be held on January 25, 2018. The SEC review period for filings of this type customarily are ten (10) calendar days, but may be longer in the discretion of the SEC. The formal Notice of Annual Meeting and a definitive proxy statement more fully describing the purposes of the Annual Meeting will be distributed to all stockholders later this month following completion of the SEC approval process.


Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

 Englewood Cliffs, NJ, USA - December 11, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will have oversight of the non-clinical aspects of the Company's drug development programs, incuding all pre- clinical studies, and will provide support for the clinical, regulatory and manufacturing activities for the Company's core pipeline assets, bertilimumab and nano-cyclosporin. Dr. Zhang joins the Company from Tesaro, Inc., Boston, MA, where he served as Director, Clinical Sciences since April 2016, and Director, Toxicology and Safety Pharmacology from Sept 2012 to March 2016.


Immune Provides Corporate Update Regarding NASDAQ US Listing Status

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP; the "Company") announced today that on December 1, 2017, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("NASDAQ") in the United States notifying the Company that the Company's common stock did not maintain a minimum closing bid price of $1.00 per share for the preceding 30 consecutive business days as required by NASDAQ Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The notice has no immediate effect on the listing or trading of the Company's common stock and the common stock will continue to trade on The NASDAQ Capital Market and NASDAQ First North Stockholm under the symbol "IMNP" at this time.


Immune Provides Corporate Update Regarding Executive Officers

Englewood Cliffs, New Jersey, USA - December 4, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP; the "Company") announced today that effective December 1, 2017, the Company entered into an employment agreement with Elliot Maza, the Company's chief executive officer ("CEO") and the Company's Board of Directors also appointed him to the additional positions of President, Principal Financial Officer and Secretary, until such time as a new Principal Financial Officer may be retained. Mr. Maza was appointed permanent CEO in September 2017, after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015.


Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer

Immune Pharmaceuticals Inc. (the "Company") announced today the public disclosure of certain information regarding its continued listing on NASDAQ US and the departure of its VP Finance.


Immune Pharmaceuticals Publishes Interim Report for the Third Quarter (July-September 2017) and Provides a Corporate Update

Englewood Cliffs, NJ - November 15, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North Stockholm: IMNP) ("Immune") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update.

Financial Results, July - September:

  • The Company recorded no revenue for the period
  • Research and development expenses were $1.2 million 
  • General and administrative expenses were $1.6 million
  • Loss from operations for the period was $2.8 million
  • Non-operating expenses, consisting of interest expense, gain or loss on changes in fair value of derivative instruments, liquidated damages on notes and loss from extinguishment of debt, were $3.2 million
  • Net loss for the period was $6.05 million
  • Net loss per ordinary share amounted to $0.53

Financial Results, January - September:

  • The Company recorded no revenue for the period
  • Research and development expenses were $3.7 million
  • General and administrative expenses were $ 4.6 million
  • Loss from operations for the period was $8.3 million
  • Non-operating expenses, consisting of interest expense, gain or loss on changes in fair value of derivative instruments, liquidated damages on notes and loss from extinguishment of debt, were $6.4 million
  • Net loss for the period was $14.7 million
  • Net loss per ordinary share amounted to $1.47

We had approximately $76,000 in cash as of September 30, 2017. We realized approximately $16 million in net proceeds from the October 23 public offering.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: